[xoo_el_inline_form active="login"]

CytoArm’s Armed-T Platform
Solves Major Challenges of T cell therapy

CytoArm addresses these critical challenges with its Armed-T platform. Instead of relying on viral vectors, our platform employs bi-functional antibodies (BsAb), which use a much smaller amount of antibody compared to traditional antibody drugs. This lower concentration minimizes the impact on the human body, reducing the risk of severe side effects, and providing a safer, more controllable therapy.

The Challenges of Current T Cell Therapies Armed-T Platform Solves

Modern T cell therapies have shown immense potential in treating various cancers, but they come with significant challenges.
Oncogenic Risk: The primary issues is the use of viral vectors for gene editing that may couse oncogenic potential, where the virus may unintentionally activate cancer-causing genes, leading to serious health concerns. By avoiding viral vectors, we eliminate the potential for viral-based oncogenesis, a significant safety concern in gene therapies.
Cost-Intensive QC: This viral approach often requires large financial investments in quality control (QC) due to the inherent risks associated with using viruses. Our non-viral approach significantly reduces the need for costly quality control processes typically required for viral-based therapies.
Difficult to Manage Side Effects: If side effects occur, current T cell therapy can be extremely difficult to manage or reverse. These high concentrations and genetic modifications can lead to unpredictable, long-term consequences for patients. With an extremely lower antibody concentration, the risk of long-lasting side effects is minimized, making our therapy far safer and easier to manage.

Advantages of CytoArm’s Armed-T Platform:

The Armed-T platform brings a revolutionary approach to T cell therapies, offering several key advantages:

CytoArm’s Armed-T platform addresses these challenges head-on, offering significant advantages over traditional T-cell therapies:
✔ High Purity: Our innovative Armed-T technology ensures that T-cell products are manufactured with a purity level exceeding 90%. This high purity enhances the safety and efficacy of the therapy, leading to more consistent and reliable patient outcomes.
✔ High Adaptability: The Armed-T platform is designed to be highly adaptable, allowing it to target a broad range of cancers and autoimmune diseases. By equipping T cells with bi-functional antibodies (BsAbs), our technology can be tailored to address over 50 different diseases, providing treatment options for patients with various types of cancers.
✔ Virus-Free Production: Unlike traditional T-cell therapies that rely on viral vectors, Armed-T uses a non-viral approach, reducing the risk of off-target effects and improving the overall safety of the therapy.
✔ Rapid Massive Manufacturing: CytoArm’s platform enables rapid production within just 10 days, significantly faster than traditional methods. This quick turnaround ensures that patients receive timely treatment, which is critical in combating aggressive cancers.
zh_TWChinese